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Abstract
Background: Bioinformatics data analysis is often using linear mixture model representing samples as additive
mixture of components. Properly constrained blind matrix factorization methods extract those components using
mixture samples only. However, automatic selection of extracted components to be retained for classification
analysis remains an open issue.
Results: The method proposed here is applied to well-studied protein and genomic datasets of ovarian, prostate
and colon cancers to extract components for disease prediction. It achieves average sensitivities of: 96.2 (sd =
2.7%), 97.6% (sd = 2.8%) and 90.8% (sd = 5.5%) and average specificities of: 93.6% (sd = 4.1%), 99% (sd = 2.2%) and
79.4% (sd = 9.8%) in 100 independent two-fold cross-validations.
Conclusions: We propose an additive mixture model of a sample for feature extraction using, in principle, sparseness
constrained factorization on a sample-by-sample basis. As opposed to that, existing methods factorize complete dataset
simultaneously. The sample model is composed of a reference sample representing control and/or case (disease)
groups and a test sample. Each sample is decomposed into two or more components that are selected automatically
(without using label information) as control specific, case specific and not differentially expressed (neutral). The number
of components is determined by cross-validation. Automatic assignment of features (m/z ratios or genes) to particular
component is based on thresholds estimated from each sample directly. Due to the locality of decomposition, the
strength of the expression of each feature across the samples can vary. Yet, they will still be allocated to the related
disease and/or control specific component. Since label information is not used in the selection process, case and
control specific components can be used for classification. That is not the case with standard factorization methods.
Moreover, the component selected by proposed method as disease specific can be interpreted as a sub-mode and
retained for further analysis to identify potential biomarkers. As opposed to standard matrix factorization methods this
can be achieved on a sample (experiment)-by-sample basis. Postulating one or more components with indifferent
features enables their removal from disease and control specific components on a sample-by-sample basis. This yields
selected components with reduced complexity and generally, it increases prediction accuracy.
Background
Bioinformatics data analysis is often based on the use of
a linear mixture model (LMM) of a sample [1-15],
whereas mixture is composed of components generated
by unknown number of interfering sources. As an
example, components can be generated during disease
progression that causes cancerous cells to produce pro-
teins and/or other molecules that can serve as early
indicators (biomarkers) representing disease correlated
chemical entities. Their correct identification may be
very beneficial for an early detection and diagnosis of
disease [16]. However, an identification of individual
components within a sample is complicated by the fact
that they can be “buried” within multiple substances. In
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can vary even several orders of magnitude [16], i.e., sin-
gle components could no longer be recognizable [1].
Nevertheless, there are the algorithms able to extract
either individual components or a group of components
with similar concentrations within a sample. These algo-
rithms are known under the name blind source separa-
tion (BSS) [17], and they commonly include
independent component analysis (ICA) [18], and nonne-
gative matrix factorization (NMF) [19]. However, BSS
methods perform unsupervised decomposition of the
mixture samples. Thus, it is not clear which of the
extracted components are to be retained for further pre-
diction/classification analysis. To this end, several con-
tributions toward solution of this problem have been
published in [1-5,8]. In [1], a matrix factorization
approach to the decomposition of infrared spectra of a
sample is proposed taking into account class labels i.e.,
the classification phase and the components inference
tasks are unified. Thus, the concept proposed in [1] is a
classifier specific. It is formulated as the multiclass
assignment problem where the number of components
equals the number of classes and must be less than the
number of samples available. As opposed to [1], the
method proposed here selects automatically the case
and control specific components on a sample-by-sample
basis. Afterwards, these components can be used to
train arbitrary classifier. In [2] gene expression profile is
modelled as a linear superposition of three components
comprised of up-regulated, down-regulated and differen-
tially not expressed genes, whereas existence of two
fixed thresholds is assumed to enable a decision to
which of the three components the particular gene
belongs. The thresholds are defined heuristically and in
each specific case the optimal value must be obtained
by cross-validation. Moreover, the upper threshold cu
and the lower one cl are mutually related through cu =
1/cl.A so p p o s e dt ot h a t ,t h em e t h o dp r o p o s e dh e r e
decomposes each sample (experiment) into components
comprised of up-regulated, down-regulated and not dif-
ferentially expressed features using data adaptive thresh-
olds. They are based on mixing angles of an innovative
linear mixture model of a sample. The method proposed
in [3] uses available sample labels (the clinical diagnosis
of the experiments) to select component(s), extracted by
independent component analysis (ICA) or nonnegative
matrix factorization (NMF), for further analysis. ICA or
NMF are used to factorize the whole dataset simulta-
neously and one selected component (gene expression
mode for ICA and metagene for NMF) is used for
further analysis related to gene marker extraction. This
component cannot be used for classification. Alterna-
tively, basis matrix with labelled column vectors (for
ICA) or row vectors (for NMF) can be used for
classification in which case the test sample needs to be
projected to space spanned by the column/row vectors,
respectively. However, in this case no feature extraction
can be performed. As opposed to ICA/NMF method
proposed in [3], the method proposed here extracts dis-
ease and control specific component from each sample
separately. Since no label information is used in the
selection process, extracted components can be used for
classification and that is the goal in this paper. The dis-
ease specific component can, however, be also retained
for further biomarker related analysis as in [3]. The
important difference is that by the method proposed
here such component can be obtained from each sample
separately while the method in [3], as well as in [4,5,8],
needs the whole dataset. The method [4] uses again ICA
(the FastICA algorithm [20]) to factorize the microarray
dataset. Extracted components (gene expression modes)
were analyzed to discriminate between those with biolo-
gical significance and those representing noise. However,
biologically significant components can be used for
further gene marker related analysis but not for classifi-
cation. The reason is that, as in [3], the whole dataset
composed of case and control samples is reduced to
several biologically interesting components only. In the
extreme case it can only be one such component. In [5]
the JADE ICA algorithm is used to decompose whole
dataset into components (gene expression modes). As in
[3,4] these components cannot be used for classification.
They are used for further decomposition into sub-
modes to identify a regulating network in the problem
considered there. We want to emphasize that the com-
ponent selected as disease specific by the method pro-
posed here can also be interpreted as a sub-mode and
used for the similar type of analysis. However, since it is
extracted from an individual and labelled sample it can
be used for the classification as well. That is the main
goal in this paper. The method in [8] again uses ICA
(the maximum likelihood with natural gradient [18]) to
extract components (gene expression modes). Similarly,
as in [3-5] these components are not used for a classifi-
cation. Instead, they are further analyzed by data clus-
tering to determine biological relevance and extract
gene markers. Similar types of comments as those dis-
cussed in relation to [3-5,8] can also be raised to other
methods that use either ICA or NMF to extract compo-
nents from the whole dataset, [6,7,10-12]. Hence,
although related to the component selection methods
[1,3-5,8] the method proposed here is dissimilar to all of
them by the fact that it extracts most interesting com-
ponents on a sample (experiment)-by-sample basis. To
achieve this, the linear mixture model (LMM) used for
components extraction is composed of a test sample
and a reference sample representing control and/or case
group. Hence, a test sample is, in principle, associated
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additive mixture of two or more components. Two of
them are selected automatically (no thresholds needed
to be predefined) as case (disease) and control specific,
while the rest are considered neutral i.e. not differen-
tially expressed. Decomposition of each LMM is enabled
by enforcing sparseness constraint on the components
to be extracted. This implies that each feature (m/z ratio
o rg e n e )b e l o n g st ot h et w oc o m p o n e n t sa tm o s t( d i s -
ease and neutral or, control and neutral). The model
formally presumes that disease specific features are pre-
sent in the prevailing concentration in disease samples
as well as that control specific features are present in
prevailing concentration in control samples. However,
the features do not have to be expressed equally strong
across the whole dataset in order to be selected as a
part of disease or case specific components. It is this
way due to the fact that decomposition is performed
locally (on a sample-by-sample basis). This should pre-
vent losing some important features for classification.
Accordingly, the level of expression of indifferent fea-
tures can also vary between the samples. Thus, postulat-
ing one or more components with indifferent features
enables their removal that is sample adaptive. As
opposed to that, existing methods try to optimize a sin-
gle threshold for a whole dataset. Geometric interpreta-
tion of the LMM based on a ref e r e n c es a m p l ee n a b l e s
automatic selection of disease and control specific com-
ponents (Figure 1 in section 1.2), without using label
information. Hence, the selected components can be
further used for disease prediction. By postulating exis-
tence of one or more components with differentially not
expressed features the complexity of the selected com-
ponents can be controlled (see discussion in section
1.7), whereas the overall number of components is
selected by cross-validation. Although the feature selec-
tion is the main goal of the proposed method, compo-
nent extracted from the sample as disease specific can
also be interpreted as a sub-mode as in [3,4]. It can be
used for further biomarker identification related analysis.
We see the linearity of the model used to describe a
sample as a potential limitation of a proposed method.
Although linear models dominate in bioinformatics, it
has been discussed in [8] that nonlinear models might
be more accurate description of biological processes.
Assumption of an availability of a reference sample
might also be seen as a potential weakness. Yet, we have
demonstrated that in the absence of expert information
the reference sample can be obtained by a simple aver-
age of all the samples within the same class. The pro-
posed method is demonstrated in sections 1.4 to 1.7 on
disease prediction problems using a computational
model as well as on the experimental datasets related to
a prediction of ovarian, prostate and colon cancers from
protein and gene expression profiles.
Methods
This section derives sparse component analysis (SCA)
approach to unsupervised decomposition of protein
(mass spectra) and gene expression profiles using a
novel mixture model of a sample. The model enables
automatic selection of the two of the extracted compo-
nents as case and control specific. They are retained for
classification. In what follows, the problem motivation
and definition are presented first. Then, LMM of a sam-
ple is introduced and its interpretation is described.
Afterwards, a two-stage implementation of the SCA
algorithm is described and discussed in details.
Figure 1 Geometrical interpretation of the linear mixture model. Concentration vectors of the linear mixture model comprised of control
reference sample and test sample, (2a) and Figure 1a, i.e. disease reference sample and test sample, (2b) and Figure 1b, are confined in a first
quadrant of the plane spanned by two mixture samples. Features (m/z ratios or genes) with prevailing concentration in disease sample are
linearly combined into component associated with the red colour relative concentration vector. Likewise, features with prevailing concentration
in control sample are combined linearly into component associated with the blue colour relative concentration vector. Features that are not
differentially expressed are combined linearly into one or more neutral components associated with the green colour relative concentration
vectors.
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As mentioned previously, bioinformatics problems often
deal with data containing components that are
imprinted in a sample by several interfering sources. As
an example, brief description of endocrine signalling sys-
tem, secreting hormones into a blood stream, is given in
[1]. Likewise, reference [21] describes how different
organs imprint their substances (metabolites) into a
urine sample. As pointed out in [1] and [16] disease
samples are combinations of several co-regulated com-
ponents (signals) originating from different sources
(organs) and disease specific component is actually “bur-
ied” within a sample. Hence we are dealing with the two
problems simultaneously: a sample decomposition (com-
ponent inference) problem and a classification (disease
prediction) problem that is based on sample decomposi-
tion. Thus, automatic selection of one or more extracted
components is of practical importance. It is also impor-
tant that component selection is done without a use of
label information in which case it can be used for
classification.
Matrix factorization is conveniently used in signal pro-
cessing to solve decomposition problems [17-19]. It is
assumed that data matrix X Î ℝ
N × K is comprised of N
row vectors representing mixture samples, whereas each
sample is further comprised of K features (m/z ratios or
genes). It is also assumed that N samples are labelled:

xn ∈ Rk,yn ∈{ 1,−1}
N
n=1, where 1 denotes positive (dis-
ease) sample and -1 stands for a negative (control) sam-
ple. Data matrix X is modelled as a product of two
factor matrices:
X = AS (1)
where A Î ℝ
N × M and S Î ℝ
M × K ,a n dM repre-
sents an unknown number of components present in a
sample. Each component

sm ∈ RKM
m=1 is represented by
a row vector of matrix S. Nonnegative relative concen-
tration profiles

am ∈ RN
+
M
m=1 are represented by column
vectors of matrix A and are associated with the particu-
lar components. Here, it will be presented how innova-
tive version of the LMM (1) of a sample

xn ∈ RkM
m=1
enables automatic selection of the case (disease) and
control specific components out of {sm}M
m=1 components
extracted by unsupervised factorization method: a two
stage SCA. The method will then be demonstrated on a
computational model as well as on a cancer prediction
problem using well known proteomic and genomic
datasets.
1.2 Novel additive linear mixture model of a sample
T h eL M M( 1 )i sw i d e l yu s e di nv a r i o u sb i o i n f o r m a t i c s
problems [1-15]. Unless constraints are imposed on A
and/or S, the matrix factorization implied by (1) is not
unique. Typical constraints involve non-Gaussianity and
statistical independence between components by ICA
algorithms [6,18], and non-negativity and sparseness
constraints by NMF algorithms, [7,11,12,19,22,23]. In
addition to that, many ICA algorithms, as well as many
NMF algorithms, also require the unknown number of
components M to be less than or equal to the number
of mixture samples N.
Depending on the context, this constraint can be con-
sidered as restrictive. There are, however, ICA methods
developed for the solution of underdetermined problems
that are known as overcomplete ICA, see Chapter 16 in
[18], as well as [24,25]. However, as discussed in details
in [18], overcomplete ICA methods also assume that
unknown components are sparse. The two exemplary
overcomplete ICA methods based on sparseness
assumption are described in [24] and [25]. In [24] it is
assumed that components are sparse and approximately
uncorrelated ("quasi-uncorrelated”). This basically
means that each feature belongs to one component
only. That is even a fairly stronger assumption than
what is used by the method proposed here. Likewise, in
maximum likelihood (ML) approach to the overcom-
plete problem in [25] it is assumed that marginal distri-
butions of the components are Laplacian. In this case
the component estimation problem (assuming the mix-
ing matrix is estimated by clustering) is reduced to lin-
ear program with equality constraint. In other words, a
probabilistic ML problem is converted into a determi-
nistic linear programming task. Hence, the overcomplete
ICA effectively becomes SCA. This further justifies our
choice of the state-of-the-art SCA method (described in
section 1.3), to be used in a component extraction task.
H e r e ,w ep r o p o s ean o v e lt y p eo ft h eL M Mm o d e l
which is composed of two samples only:

xcontrol
x

= AcontrolScontrol (2a)

xdisease
x

= AdiseaseSdisease (2b)
The first sample is a reference sample representing
control group, xcontrol Î ℝ
K, in (2a) and case (disease)
group, xdisease Î ℝ
K, in (2b). The second sample is actual
test sample: x ∈

xn ∈ RkN
n=1. Coefficients of matrices
Acontrol ∈ R2×M
+ and Adisease ∈ R2×M
+ in (2a) and (2b)
refer to the amount of relative concentration at which
related components are present in the mixture samples
x and xcontrol in (2a) or x and xdisease in (2b). Source
matrices Scontrol Î ℝ
M × K and Sdisease Î ℝ
M × K contain
(as row vectors), disease- and control specific
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components. Number of components M is assumed to
be greater than or equal to 2. Evidently, for M = 2 exis-
tence of differentially not expressed components is not
postulated. Importance of postulating components with
indifferent features is to obtain less complex disease and
control specific components used for classification (see
also discussion in section 1.7). These components
absorb features that do not vary substantially across the
sample population. These features are removed automa-
tically from each sample. The concentration is relative
due to the fact that BSS methods enable estimation of
the mixing and source matrices up to the scaling con-
stant only. Therefore, it is customary to constrain the
column vectors of the mixing matrix to unit ℓ2 or ℓ1
norm. The LMM proposed here is built upon an impli-
cit assumption that disease specific features (m/z ratios
or genes) are present in prevailing concentration in dis-
ease specific samples and in minor concentration in
control specific samples. As opposed to that, control
specific features are present in prevailing concentration
in control specific samples and in minor concentration
in disease specific samples. Features that are not differ-
entially expressed are present in similar concentrations
in both control and disease specific samples. These
groups of features constitute components, whereas simi-
larity of their concentration profiles enables automatic
selection of the components extracted by unsupervised
factorization. The assumption on the prevailing concen-
trations of up- and down-regulated features needs to be
understood in the relative sense. It is justified on the
basis of locality of proposed method since the compo-
nents are extracted on a sample-by-sample basis. Thus,
to be allocated in the same component (a case or a con-
trol specific one) feature does not need to be expressed
in each sample equally strong. Since the LMMs (2a)/
(2b) considered here are comprised of two samples only
the non-negative mixing vectors are confined in the first
quadrant of the plane spanned by control reference
sample and test sample, see Figure 1a, or by disease
reference sample and test sample, see Figure 1b. Thus,
upon decomposition of the LMM (2a) into M compo-
nents, the one associated with the mixing vector that
confines the maximal angle with respect to the axis
defined by control reference sample is selected as a dis-
ease specific component, Figure 1a. As opposed to that,
the one associated with the mixing vector that confines
the minimal angle with respect to the axis defined by
control reference sample is selected as a control specific
component. When decomposition is performed with
respect to a disease reference sample, LMM (2b), the
logic for an angle-based automatic selection of disease
and control specific components is the opposite, see Fig-
ure 1b. The components not selected as disease or
control specific are considered neutral i.e. not differen-
tially expressed. Thus, LMMs (2a)/(2b) enable automatic
selection of the components extracted by unsupervised
factorization of mixture samples. Unlike selection
method presented in [2] that is based on fixed thresh-
olds which need to be determined by cross-validation,
the thresholds (mixing angle s )u s e di nt h em e t h o dp r e -
sented here are sample adaptive. An assumption that
each feature is contained in disease specific and one of
the neutral components, or control specific and one of
the neutral components, represents a sparseness con-
straint. It enables solution of the related BSS problems
through, in principle, two-stage SCA method described
in section 1.3. However, sparseness constraint is not jus-
tified by mathematical reasons only but also, as empha-
sized in [3,6,11,12], by the biological reasons. As noted
in [6] this is necessary if underlying component (source
signal) is going to be indicative of ongoing biological
p r o c e s s e si nas a m p l e( c e l l ,t i s s u e ,s e r u m ,e t c . ) .T h e
same conjecture has actually also been used in a three
components based gene discovery method in [2]. In this
respect, the sparseness constrained NMF methods for
microarray data analysis proposed in [7,11,12] also
assume the same working hypothesis. As discussed in
[11,12], it is the sparseness constraint that enabled bio-
logical relevance of obtained results. In microarray data
analysis enforcement of sparseness constraint is biologi-
cally justified due to the fact that more sparse S gives
rise to metagenes (if factorization is performed by
NMF), or to the expression modes (if factorization is
performed by ICA), that comprise few dominantly co-
expressed genes which may indicate good local features
for specific disease [11]. A subtle interpretation of the
reference-based mixture model (2a)/(2b) reveals its sev-
eral profound characteristics. Since placement of the
features to each of the two or more postulated compo-
nents is based on sample adaptive thresholds (decompo-
sition is localized), one gene (or m/z ratio) may be
highly up-regulated in a case of one sample and signifi-
cantly less expressed in a case of an another sample.
Yet, if it is contained in prevailing concentration in both
samples it will be contained in both cases in the compo-
nent automatically selected as disease or control specific.
Moreover, sample adaptive component (feature) selec-
tion enables that features selected as up- (or down)-
regulated in one sample be less (or more) expressed
than differentially not expressed features in another
sample. Thus, extracted components selected as disease
or control specific are composed of multiple features
with different expression levels and joint discriminative
p o w e rr a t h e rt h a no fs e v e r a l( o re v e ns i n g l e )f e a t u r e s
only.
For disease prediction, disease and control specific
components can be used to train a classifier. The reason
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respect to different reference samples and, thus, carry
on different but specific information. Hence, proposed
method yields four components to be retained for classi-
fier training. In accordance with Figure 1 they are
denoted as sdisease
control ref.;n, scontrol
control ref.;n, scontrol
disease ref.;n,a n d
sdisease
disease ref.;n,w h e r en denotes index of a test sample xn
used in current decomposition. Components extracted
from N mixture samples, form four sets of labelled fea-
t u r ev e c t o r sa sf o l l o w s :

sdisease
control ref.;n,yn
N
n=1
,

scontrol
disease ref.;n,yn
N
n=1
,

scontrol
disease ref.;n,yn
N
n=1
and

sdisease
disease ref.;n,yn
N
n=1
. One or more classifiers can be
trained on them and the one with the highest accuracy
achieved through cross-validation is selected for a dis-
ease diagnosis.
Selection of the unknown number of components M is
generally non-trivial problem in a matrix factorization
and is the part of a model validation procedure. M is
selected through cross-validation and postulated to be 2,
3, 4 or 5 because it directly determines the number of
features used for classification. This follows from pre-
viously described interpretation of the LMM (2a) and
(2b). Since disease prediction is based on four compo-
nents selected as disease and control specific it is impor-
tant that they are composed of features with the high
discriminative power. It means that they should contain
features which are truly disease or control specific. The
component considered here as disease or control speci-
fic (as well as neutral) can actually be composed of fea-
tures (m/z ratios or genes) belonging to multiple
substances (metabolites, analytes) that share similar rela-
tive concentrations. This is practically important since it
makes decomposition much less sensitive to an underes-
timation of the true total number of substances present
in a sample. By setting the number of substances to pre-
defined value M,p r o p o s e dm e t h o di se n f o r c i n gs u b -
stances with similar concentrations to be linearly
combined into one more complex components com-
posed of disease, neutral or control specific features.
Provided that concentration variability of these features
across the samples is small, it would suffice to select
overall number of components as M = 3 or even M =2 .
(In the latter case, the existence of differentially not
expressed features is not postulated at all). However,
since we are dealing with biological samples it is more
realistic to expect that relative concentrations could vary
across the sample population. This is illustrated in Fig-
ures 1a and 1b by ellipsoids around vectors that repre-
sent average concentration profiles of each group of
features (components). As seen from Figure 1, some
features considered neutral can be present in the pre-
vailing concentration in a certain number of samples
than the features considered in a majority of the sam-
ples as disease (or control) specific. To partially remove
such features from disease and/or control specific com-
ponents, an unknown number of components M should
be increased to M = 4 or perhaps even to M =5 .T h u s ,
existence of two or three neutral components should be
postulated. This is expected to yield less complex dis-
ease and control specific components and that is in
agreement with the principle of parsimony (see also dis-
cussion in section 1.7). Model validation presented in
section 1.4 suggests that this, indeed, is the case when
concentration variability across the samples is signifi-
cant. When it comes to the real world datasets, the
information about number of components will not be
known in advance. The strategy to comply with this
uncertainty is to use the cross-validation and to verify
whether increased number of components M indeed
contributed to increased accuracy in disease prediction.
1.3 Sparse component analysis algorithm
Proposed feature extraction/component selection
method is based on a decomposition of LMMs (2a)/(2b)
comprised of two samples (reference sample and test
sample) into M ≥ 2 components. From the BSS point of
view this yields determined BSS problem when M =2
and underdetermined BSS problem, when M ≥ 3[ 2 6 ,
27, Chapter 10 in 17]. The enabling constraint for sol-
ving underdetermined BSS problems is a sparseness of
the components and the methods are known under the
common name as sparse component analysis (SCA) [26-
29, Chapter 10 in 17]. As commented at the beginning
of section 1.2 the overcomplete ICA, [Chapter 16 in 18,
24, 25], is basically reduced to SCA and also demands
sparse sources. SCA has already been applied to micro-
array data analysis in [3,6,7,11,12]. It has also been used
in [22,23] to extract more than two components from
the two mixture samples of nuclear magnetic resonance
and mass spectra. A sparseness constraint implies that
each particular feature point k = 1, ...,K (m/z ratio or
gene) belongs to the several components only. To this
end, for the two-samples based LMMs (2a)/(2b) used
here, it is assumed that each feature point belongs to at
most two components: either disease specific and neu-
tral or control specific and neutral. From the viewpoint
of biology, a plausibility of this assumption has been ela-
borated before.
Algorithmic approaches used to solve underdeter-
mined BSS problem associated with (2a)/(2b) belong to
the two main categories: (i) estimating concentration/
mixing matrix and component matrix simultaneously by
minimizing data fidelity terms  X − AcontrolScontrol 2
F or
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F,w h e r eX follows from the left side
of (2a) or (2b). A minimization is usually done through
the alternating least square (ALS) methodology with
sparseness constraint imposed on source matrices Scon-
trol and Sdisease, [19,22,23,30-32]; (ii) estimating concen-
tration/mixing matrices first by clustering and source/
component matrices afterwards by solving underdeter-
mined system of linear equations through minimization
of the ℓp norm, 0 <p ≤ 1, of the column vectors sk Î
ℝ
M of Scontrol and Sdisease, [25-29,33-35]. As discussed in
[6], a sparseness constrained minimization of the data
fidelity term is sensitive to the choice of a sparseness
constraint. On the other side, it has been recognized in
[33-35] that accurate estimation of the concentration
matrix enables accurate solution of even determined
BSS problems. To this end, selection of feature points
where only single component is present is of a special
importance. At these points, feature vector and appro-
priate mixing vector are collinear. For example, if fea-
ture k belongs to component m then: xk ≈ am smk. Thus,
clustering of a set of single component points (SCPs)
ought to yield an accurate estimate of the mixing
matrix. Its columns are represented by cluster centroids.
It has been demonstrated in [33] that such estimation of
the mixing matrix, where hierarchical clustering was
used, yields more accurate solution of determined BSS
problem: S = pinv(A)X, than the one obtained by ICA
algorithms. Thus, selection of SCPs is of an essential
importance for accurate estimation of the mixing
matrix. Such feature points are identified from the over-
all number of K points using geometric criterion based
o nt h en o t i o nt h a ta tt h e mr e a la n di m a g i n a r yp a r t so f
the mixture samples point either in the same or in the
opposite direction [33,34]. Since protein (mass spectra)
and gene expression levels are real sequences an analytic
continuation [22] of mixture samples:
xn  →˜ xn = xn +
√
−1H(xn) is used to obtain complex
representation, where H(xn) denotes Hilbert transform
of xn. The feature point k will be selected to the set of J
SCPs provided that the following criterion is satisfied:
 
 

R(˜ xk)
TI(˜ xk)

R(˜ xk)



I(˜ xk)


 
 

≥ cos( θ) k ∈{ 1,...,K}
where R(˜ xk) and I(˜ xk) denote real and imaginary part
of ˜ xk respectively, ‘T’ denotes transpose operation, 
R(˜ xk)

and

I(˜ xk)

denote ℓ2-norms of R(˜ xk) and I(˜ xk)
while Δθ stands for the angular displacement from
direction of either 0 or π radians. Evidently, Δθ deter-
mines quality of the selected SCPs and, thus, accuracy
of the estimation of the mixing matrices Acontrol and
Adisease. Setting Δθ to a small value (e.g., to an equiva-
lent of 1
0 ) enforces, with an overwhelming probability,
the selection of feature points that contain one compo-
nent only. If, however, all the components are not pre-
sent in at least one feature point alone it may occur that
corresponding columns of the mixing matrices will be
estimated inaccurately. This problem can be alleviated
by increasing the value of Δθ in which case the selected
feature points may not contain one component only,
but may rather be composed of one dominant compo-
nent and one or more components present in a small
amount.
Thus, in practice, Δθ needs to be selected through a
cross-validation. In the experiments described in sec-
tions 1.4 to 1.7, Δθ has been selected from the set of
radians equivalent to {1
0,3
0,5
0}t o g e t h e rw i t hap o s t u -
lated number of components M and with a regulariza-
tion parameter related to sparseness constraint imposed
on Scontrol and Sdisease ( s e ee q .( 3 )b e l o w ) .H i e r a r c h i c a l
clustering implemented by MATLAB clusterdata com-
mand (with a ‘cosine’ distance metric and ‘complete’
linkage option) has been used to cluster the set of
selected J feature points with a single component
belonging. Number of clusters has been set in advance
to equal the postulated number of components M. Clus-
ter centres represent estimated concentrations vectors

am ∈ R2
+
M
m=1. It is also possible to use other clustering
methods, such as k-means, as an alternative to hierarchi-
cal clustering. The problem with k-means, however, is
that it is non-convex and its performance strongly
depends on the initial value selected for cluster cen-
troids. On the other side, hierarchical clustering pro-
duces repeatable result i.e. for a given set of SCPs it
yields the same result for the mixing matrix in each run.
Since the number of selected SCPs is modest, the com-
putational complexity of hierarchical clustering
approach is not too high. That is why hierarchical clus-
tering is used to estimate the mixing matrices in (2a)
and (2b). After mixing matrices are estimated, estima-
tion of the component matrices proceeds by minimizing
sparseness constrained cost functions:
ˆ Scontrol = min
S
	
1
2
 

ˆ AcontrolS −

xcontrol
x
 


2
F
+ λ S 1


(3a)
ˆ Sdisease = min
S
	
1
2
 

ˆ AdiseaseS −

xdisease
x
 


2
F
+ λ S 1


(3b)
where the hat sign denotes estimates of the model
variables Acontrol/Adisease and Scontrol/Sdisease. Problems
(3) relate to the sparseness constrained solution of the
underdetermined systems of linear equations. For a
decomposition of gene expression profiles, a non-nega-
tivity constraint is additionally imposed on S: S ≥ 0.
Problem (3) can be solved by the LASSO algorithm [36]
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linear equations [37]. Here, for problem (3) we have
used the iterative shrinkage thresholding (IST) type of
method [38], with a MATLAB code available at [39].
This approach has been shown to be fast and it can be
easily implemented in batch mode such as (3a)/(3b) i.e.
as a solving of all K systems of equations simulta-
neously. In relation to standard IST methods, the
method [38] has guaranteed better global rate of conver-
gence. In addition to that, through the effect of itera-
tions, it shrinks to zero small nonzero elements of S
that are influenced by noise. This prevents them to
determine level of sparseness of S. As discussed in [6]
this shrinking operation is important in preventing
selection of less sparse S over the sparse version of S.
With non-negativity constraint S ≥ 0 problem (3)
becomes a quadratic program. Thus, we have used a
gradient descent with projection onto non-negative
orthant: max(0,S). A sparsity of the solution is con-
trolled by the parameter l. There is a maximal value of
l (denoted by lmax here) above which the solution of
the problems (3) is maximally sparse, i.e. it is equal to
zero. Thus, in the experiments reported in sections 1.5
to 1.7 the value l has been selected by cross-validation
(together with Δθ and M) with respect to lmax as: lÎ
{10
-2·lmax,1 0
-4·lmax, 10-
6·lmax}. We conclude this sec-
tion by an observation that the situation suggested in
[6]: X = AS = A
pseuS
pseu,w h e r e( A
pseu, S
pseu) represents
alternative factorization of X such that S
pseu would be
less sparse than S, during minimization of (3) cannot
occur. That is due to IST algorithm [38] as well as due
to accurate estimation of the mixing matrices that is
enabled by clustering set of the SCPs. First, this is a
consequence of the fact that a shrinking operation used
by IST algorithm [38] imposes sparseness constraint of
the type given by eq.(7) in [6]:
0 ≤ στ(sk)=
numberofelementsofsk ≤ τ · smax
k
numberofelementsofsk
≤ 1,τ ∈ [0,1],
i.e. small nonzero elements of sk are set to zero. This
prevents selection of less sparse S
pseu over sparser S.
Second, SCA method used here is a two-stage method
where A is estimated accurately by clustering on a set of
SCPs. This, in addition to a sparseness measure dis-
cussed above, prevents estimate of S to deviate from the
true value significantly. It is this way because when S is
being estimated by means of IST algorithm the very
estimate of A is fixed. As opposed to the case when A
and S are estimated simultaneously, as in [6], an esti-
mate of A can’t now be adjusted by the algorithm to
some value A
pseu that will counteract changes in S.
Hence, selecting S
pseu w o u l di n c r e a s ead a t af i d e l i t y
term in the cost function. Thus, situation as suggested
in [6]: X = AS = A
pseuS
pseu can’to c c u r .Ap r o p o s e d
two-stage SCA approach to feature extraction/compo-
nent selection is in a concise form presented in Table 1.
A MATLAB code is posted in the Additional Material
Files section accompanied with the paper as Additional
File 1.
Results and Discussion
This section presents model validation procedure. It is
demonstrated how increased number of postulated com-
ponents retains, or slightly improves, prediction accu-
racy when concentration variability of the features
across the sample population is significant. Moreover,
an increased number of postulated components yields
the disease and control specific components used for
classification with a smaller number of features. This is
in an agreement with the principle of parsimony which
states that less complex solution ought to be preferred
over the more complex one. Proposed method for fea-
ture extraction/component selection is also applied to a
prediction of ovarian, prostate and colon cancers from
the three well-studied datasets. Prediction accuracy (sen-
sitivity and specificity with standard deviations) is esti-
mated by 100 independent two-fold cross-validations.
Proposed SCA component selection method is com-
pared (favourably) against state-of-the-art predictors
tested on the same datasets including our implementa-
tion of methods proposed in [1,2]. Regarding our imple-
mentation of a predictive matrix factorization method
[1], we have used the MATLAB fminsearch function
to minimize the negative value of the target function
suggested in [1] while selecting the threshold vector. We
have set the TolFun to 10
-10,t h eTolX to 10
-10 and
the MaxFunEvals to 10,000. An initial value of the
two-dimensional threshold vector has been set to [0 0]
T.
Regarding a gene discovery method proposed in [2] we
have cross-validated three values of the threshold cu Î
{ 2 ,2 . 5 ,3 . 0 }( cl is set automatically cl =1 / cu). The best
result is presented in section 1.7. Regarding a compari-
son of a proposed component selection method against
many methods in sections 1.5 to 1.7, our intention has
been to provide a brief description of the methods and
to provide fair comparison given the fact that code for
compared methods has not been available to us. That
actually was the main reason for choosing a well known
datasets such as in 1.5 to 1.7, since a rich list of pub-
lished results exists for them. We are aware of the fact
that results by many other methods were obtained by
different cross-validation settings. Therefore, our reason-
ing is that fair comparison is possible as long as the
results to be compared were obtained on the same data-
sets under conditions that favor less the method pro-
posed here. That is the reason why we have chosen to
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yield the least optimistic result. Thus, if such results are
compared favorably against those obtained under milder
(ten- and three-fold) cross-validation settings, conclu-
sion can be made that proposed feature extraction/com-
ponent selection method represents contribution to the
field. As opposed to the two-fold cross-validation
applied here, cross-validation details for many cited
results were not specified. Sometimes ten-fold, or three-
fold, cross-validations have been performed. Hence, it is
believed that performance assessment of proposed com-
ponent selection method is more realistic than perfor-
mance of the majority of methods cited in comparative
analysis. For each of the three types of cancers three
classifiers were trained on four sets of extracted compo-
nents:

sdisease
control ref.;n,yn
N
n=1
,

scontrol
control ref.;n,yn
N
n=1
,

scontrol
disease ref.;n,yn
N
n=1
and

sdisease
disease ref.;n,yn
N
n=1
. The three classifiers used were lin-
ear SVM and nonlinear SVM with radial basis function
(RBF) and polynomial kernels [40], with C =1 .P a r a -
meters of the nonlinear SVM classifiers were selected by
cross-validation. Prior to the classification, the sets of
extracted components were standardized to zero mean
and unit variance. Although the standardization across
the features is used more often, a standardization across
the components (they coincide with the samples from
which they were extracted) has been performed here. It
yielded much better accuracy and such a fact has also
been observed in Chapter 18 in [41], where in microar-
ray data analysis standardization across the samples has
also been preferred over standardization across the fea-
tures. In comparative performance analysis presented in
Tables 2, 3 and 4 the best result (obtained by a nested
two-fold cross-validation with respect to parameters of
the classifiers, single component selection threshold Δθ,
regularization constant l a n dp o s t u l a t e dn u m b e ro f
components M ) on all four sets of selected components
has been used to represent component selection method
proposed here. Since many components extracted by
other combinations of the parameters yielded also good
prediction accuracy we have posted complete results in
the Additional Material Files section (Additional Files 2,
3, 4 and 5) accompanied with the paper. Reference sam-
ples used to represent disease and control groups were
Table 1 A mixture model with a reference-based algorithm for feature extraction/component selection
Inputs.

xn ∈ Rk,yn ∈{ 1,−1}
N
n=1
samples and sample labels, where K represents number of feature points (m/z ratios or genes).
xcontrol Î ℝ
K and xdisease Î ℝ
K representing control and disease (case) groups of samples.
Nested two-fold cross-validation. Parameters: single component points (SCPs) selection threshold in radian equivalents of Δ θ {1
0,3
0,5
0};
regularization constant lÎ {10
-2lmax,1 0
-4lmax,1 0
-6lmax}; number of components M Î{2, 3, 4, 5}; parameters of selected classifier.
Components selection from mixture samples.
1. ∀x ∈

xn ∈ RkN
n=1
form a linear mixture models (LMMs) (2a) and (2b).
2. For LMMs (2a)/(2b) select a set of single component points for a givenΔθ.
3. On sets of SCPs use hierarchical clustering (other clustering methods can be used also) to estimate mixing matrices Acontrol and Adisease
for a given M.
4. Estimate source matrices Scontrol and Sdisease by solving (3a) and (3b) respectively for a given regularization parameter l.
5. Use minimal and maximal mixing angles estimated from mixing matrices Acontrol and Adisease to select, following the logic
illustrated in Fig. 2a and Fig. 2b, disease and control specific components: sdisease
control ref.;n, scontrol
control ref.;n, scontrol
disease ref.;n and sdisease
disease ref.;n.
End of component selection.
End of nested two-fold cross-validation.
Table 2 Comparative performance results in ovarian cancer prediction. Sensitivities and specificities were estimated
by 100 two-fold cross-validations (standard deviations are in brackets).
Method Sensitivity/Specificity/Accuracy
Proposed method M =3 ,Δθ =5
0
l =1 0
-4lmax
Linear SVM
Sensitivity: 96.2 (2.7)%; specificity: 93.6 (4.1)%; accuracy: 94.9%
Control specific component extracted with respect to a cancer reference sample.
Proposed method M =4 ,Δθ =3
0
l =1 0
-6lmax
Linear SVM
Sensitivity: 95.4 (3)%; specificity: 94 (3.7)%; accuracy:94.7%
Control specific component extracted with respect to a cancer reference sample.
[1] Sensitivity: 81.4 (7.1)%; specificity: 71.7 (6.6)%
[42] Sensitivity: 100%; specificity: 95% (one partition only: 50/50 training; 66/50 test).
[44] Accuracy averaged over 10 ten-fold partitions: 98-99% (sd: 0.3-0.8)
[13] Sensitivity: 98%, specificity: 95%, two-fold CV with 100 partitions.
[45] Average error rate of 4.1% with three-fold CV.
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xdisease =
1
N1
N1
i=1 xi where xi ∈

xn : yn =1
N1
n=1,a n d
control group, xcontrol =
1
N2
N2
i=1 xi where
xi ∈

xn : yn =1
N2
n=1 and N1 + N2 = N. We thought this
is the most fair approach in the absence of any prior
information that could suggest which labelled sample
could serve as a gold standard. We conclude this section
by providing assessment of the computational complex-
ity of proposed method. It has been implemented in
MATLAB 7.7 environment on a desktop computer
based on 3 GHz dual core processor and 2 GB of RAM.
Processing of proteomic and genomic datasets used in
sections 1.5 to 1.7 took 10, 7 and 3 minutes respectively.
1.4 Model validation
This section presents model validation results obtained
on simulated data using LMM (2a)/(2b). To this end,
each mixture sample has been composed of ten ortho-
gonal components comprised of K = 15000 features.
The orthogonality implies that each feature belongs to
one component only. By a convention, the first compo-
nent has been selected to contain disease specific fea-
tures, the tenth component to contain control specific
features and the components two to nine contain fea-
tures that are not differentially expressed and share
similar concentrations in control and disease labelled
samples. A concentration variability across the sample
population is simulated using the following model for
disease group of samples:
xn =
M
m−1 sin
2(θnm)sm
and for control group of samples:
xn =
M
m−1 cos2(θnm)sm (4)
Thus, by controlling the mixing angles {θnm}
N,M
n=1,m=1 the
amount of a concentration of each component in dis-
ease and control samples is controlled. Also amount of
concentration variability is controlled by selecting
{θnm}
N,M
n=1,m=1 to be confined within (non-) overlapping
angular sectors. Note that (4) implies that component sm
Table 3 Comparative performance results in prostate cancer prediction. Sensitivities and specificities were estimated
by 100 two-fold cross-validations (standard deviations are in brackets).
Methods Sensitivity/Specificity/Accuracy
Proposed method M =5 ,
Δθ =1
0
l =1 0
-4lmax Linear SVM
Sensitivity: 97.6 (2.8)%; specificity: 99 (2.2)%; accuracy: 98.3%
Control specific component extracted with respect to a cancer reference sample.
Proposed method M =4 ,
Δθ =1
0
l =1 0
-4lmax Linear SVM
Sensitivity: 97.7 (2.3)%; specificity: 98 (2.4)%; accuracy: 97.9%
Control specific component extracted with respect to a cancer reference sample.
[1] Sensitivity: 86 (6.6)%; specificity: 67.8(12.9)%; accuracy: 76.9%.
[46] Sensitivity: 94.7%; specificity: 75.9%; accuracy: 85.3%. 253 benign and 69 cancers. Results were obtained on
independent test set comprised of 38 cancers and 228 benign samples.
[47] Sensitivity: 97.1%; specificity: 96.8%; accuracy: 97%. 253 benign and 69 cancers. Cross-validation details not reported.
[45] Average error rate of 28.97 on four class problem with three-fold cross-validation.
Table 4 Comparative performance results in colon cancer prediction. Sensitivities and specificities were estimated by
100 two-fold cross-validations (standard deviations are in brackets).
Methods Sensitivity/Specificity/Accuracy
Proposed method M =2 ,Δθ =1
0
RBF SVM (s
2 = 1200, C = 1)
Sensitivity: 90.8 (5.5)%, specificity: 79.4 (9.8)%; accuracy: 85.1%
Control specific component extracted with respect to a cancer reference sample.
Proposed method M =4 ,Δθ =5
0 l =1 0
-
2lmax
RBF SVM (s
2 = 1000, C = 1)
Sensitivity: 89.8 (6.2)%, specificity: 78.6 (12.8)%; accuracy: 84.2%.
Control specific component extracted with respect to a control reference sample.
[1] Sensitivity: 89.7 (6.4)%, specificity: 84.3 (8.4)%; accuracy = 87%. 100 two-fold cross-validations.
[2] Sensitivity: 92.1 (4.7)%, specificity: 85 (10.1)%; accuracy: 88.55%. 100 two-fold cross-validations. cu=
2.0.
[48] Sensitivity: 92-95% calculated from Figure 5. Specificity not reported.
[15] Accuracy 85%. Cross-validation details not reported.
[50] Accuracy 82.5%, ten-fold cross-validation (RFE with linear SVM).
[51] Accuracy 88.84%, two-fold cross-validation (RFE with linear SVM and optimized penalty parameter C).
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overall concentration of 100%. To simulate biological
variability between the samples, the relative concentra-
tion has been varied across the sample population, where
disease and control groups contained 100 samples each.
The concentration vectors were overlapping in the mix-
ing angle domain i.e. a concentration vector for disease
specific features was confined in the sector of [50
0,
89.99
0], for the neutral features it was in the sector of
[25
0,65
0] and for control specific features it was confined
in the sector of [0.01
0,40
0]. Thus, amount of overlap
between concentration profiles was significant, implying
that in many cases neutral features were contained in
greater concentrations in disease labelled samples than
disease specific features, as well as that neutral features
were contained in greater concentrations in control
labelled samples than control specific features. Figures 2a
and 2b show disease prediction results using four
extracted disease and control specific components with
the postulated overall number of components equal to M
= 2 (red bars), M = 3 (green bars), M = 4 (blue bars) and
M = 5 (magenta bars). Reference samples used in LMM
(2a)/(2b) were obtained by averaging all the samples in
control i.e. disease group. Results reported in terms of
sensitivity (Figure 2a) and specificity (Figure 2b) were
obtained by the linear support vector machine (SVM)
classifier using 100 independent two-fold cross-valida-
tions. SCPs selection parameter has been set to Δθ =3
0
and sparseness regularization parameter in (3a)/(3b) to l
=1 0
-6·lmax. These parameters were not selected through
cross-validation since the purpose of the computational
experiment has been to evaluate influence of the assumed
number of components M to the prediction accuracy
when concentration varies across the sample population.
The presented results demonstrate that greater number
of postulated components does not decrease prediction
accuracy (in the average it is even slightly increased).
However, increased number of postulated components M
reduces the number of features contained in disease and
control specific components selected for classification. As
discussed previously, a greater M yields less complex dis-
ease and control specific components. Following the
principle of parsimony such solution should be preferred
over the more complex ones that are obtained for smaller
M. Thus, selected disease and control specific compo-
nents are expected to be more discriminative and less
sensitive to over-fitting when the number of postulated
components is increased. In practical implementation of
the proposed approach to component selection the opti-
mal number of overall components needs to be evaluated
by a cross-validation. In the three real world experiments
reported below the number of components has been
selected by cross-validation from M Î { 2 ,3 ,4 ,5 } .I fa
prediction accuracy achieved for the two values of M is
approximately equal, it is better to prefer components
extracted from the samples with a greater value of M.
1.5 Ovarian cancer prediction from a protein mass
spectra
Low resolution surface-enhanced laser desorption ioni-
zation time-of-flight (SELDI-TOF) mass spectra of 100
controls and 100 cases have been used for ovarian can-
cer prediction study [42]. See also the website of the
clinical proteomics program of the National Cancer
Figure 2 model validation. Sensitivities, Figure 2a, and specificities, Figure 2b, (with standard deviations as error bars) estimated by linear SVM
classifier and 100 independent two-fold cross-validations using two disease specific and two control specific components. Components were
extracted from the linear mixture models based on control reference (c.r.) sample, model (2a), and disease reference (d.r.) sample, model (2b),
where each sample was comprised of ten orthogonal components containing K=15000 features. One component contained in prevailing
concentration disease specific features, one control specific features and eight components contained features equally expressed in control and
disease labelled samples. Relative concentration (expressed through a mixing angle) across the sample population has been: for disease specific
features in the range of 50
0 to 89.99
0; for differentially not expressed features in the range of 25
0 to 65
0; and for control specific features in the
range of 0.01
0 to 40
0. Assumed overall number of components has been M=2 (red bars), M = 3 (green bars), M=4 (blue bars) and M =5
(magenta bars).
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as “Ovarian 4-3-02”. All spectra were baseline corrected.
Thus, some intensities have negative values. Table 2
presents the best result obtained by the proposed SCA-
based component selection method together with results
obtained for the same dataset by competing methods
reported in cited references as well as by predictive fac-
torization method proposed in [1]. Described SCA
method has been used to extract four sets of compo-
nents with the overall number of components M
assumed to be 2, 3, 4 and 5. Figure 3 shows sensitivities
and specificities estimated by 100 independent two-fold
cross-validations using linear SVM classifier which
yielded the best results compared against nonlinear
SVM classifiers based on polynomial and RBF kernels.
Performance improvement is visible when assumed
number of components is increased from 2 to 3, 4 or 5.
The error bars are dictated by the sample size and
would decrease with a larger sample. Thus, the mean
values should be looked at to observe the trend in per-
formance as a function of M. The best result (shown in
Table 2) has been obtained with the linear SVM classi-
fier for M = 3 with sensitivity of 96.2% and specificity of
93.6%, but results with the very similar quality have
been obtained for several combinations of the para-
meters M, Δθ and l, see Figure 3, most notably M =4
(see second column in Table 2 and the Additional File
2). As seen in Table 2, only [13] reported better result
for a two-fold cross-validation with the same number of
partitions. There, a combination of genetic algorithm
and k-nearest neighbours method, originally developed
for mining of high-dimensional microarray gene expres-
sion data, has been used for analysis of proteomics data.
However, the method [13] is tested on proteomic
ovarian cancer dataset only, while the method proposed
here exhibited excellent performance in prediction of
prostate cancer from proteomic data (reported in sec-
tion 1.6), as well as on colon cancer from genomic data
(presented in section 1.7). The method shown in [42]
used 50 samples from the control group and 50 samples
from the ovarian cancer group to discover a pattern that
discriminated cancer from non-cancer group. This pat-
tern has then been used to classify an independent set
of 50 samples with ovarian cancer and 66 samples unaf-
fected by ovarian cancer. In [44], a fuzzy rule based clas-
sifier fusion is proposed for feature selection and
classification (diagnosis) of protein mass spectra based
ovarian cancer. Demonstrated accuracy of 98-99% has
been estimated through 10 ten-fold cross-validations (as
opposed to 100 two-fold cross-validations used here).
Moreover, as demonstrated in sections 1.6 and 1.7, the
method proposed here exhibited good performance on
diagnosis of prostate and colon cancers from proteomic
and gene expression levels, respectively. In [45], a clus-
t e r i n gb a s e dm e t h o df o rf e ature selection from mass
spectrometry data is derived by combining k-means
clustering and genetic algorithm. The method exhibited
an accuracy of 95.8% (error rate 4.1%), but this has been
assessed through three-fold cross-validations (as
opposed to two-fold cross-validations used here).
1.6 Prostate cancer prediction from a protein mass
spectra
Low resolution SELDI-TOF mass spectra of 63 controls:
no evidence of cancer with prostate-specific antigen
(PSA)<1, and 69 cases (prostate cancers): 26 with
4<PSA<10 and 43 with PSA>10, have been used for
prostate cancer prediction study [46]. There are
Figure 3 ovarian cancer prediction. Sensitivities (a) and specificities (b) (with standard deviations as error bars) estimated in ovarian cancer
prediction from protein expression levels using 100 independent two-fold cross-validations and linear SVM classifier. Four sets of selected
components were extracted by SCA-based factorization using LMMs (2a) and (2b) with control reference (c.r.) and disease reference (d.r.) samples
respectively, where the overall number of components M has been set to 2 (red bars), 3 (green bars), 4 (blue bars) and 5 (magenta bars).
Optimal values of the parameters l and Δθ were used for each M. Performance improvement is visible when number of components is
increased from 2 to 3, 4 or 5.
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(4<PSA<10) available as well (see the website of the
clinical proteomics program of the NCI, [43]), in dataset
labelled as “JNCI_Data_7-3-02”. However, in the two-
class comparative performance analysis problem
reported here these samples were not used. Proposed
SCA-based method has been used to extract four sets of
components with the overall number of components M
assumed to be 2, 3, 4 and 5. The best result has been
achieved for M = 5 with sensitivity of 97.6% and specifi-
city of 99%, but results with the very similar quality
have been obtained for several combinations of the
parameters M, Δθ and l,( s e eF i g u r e4a n dt h eA d d i -
tional File 3). Table 3 presents two best results achieved
by the proposed SCA-based approach to component
selection together with the results obtained by compet-
ing methods reported in cited references. Linear SVM
classifier yielded the best results when compared against
nonlinear SVM classifiers based on polynomial and RBF
kernels. According to Table 3, comparable result
(although slightly worse) is in the reference [47] only.
The method [47] is proposed for analysis of mass spec-
tra for screening of prostate cancer. The system is com-
posed of three stages: a feature selection using statistical
significance test, a classification by radial basis function
and probabilistic neural networks and an optimization
of the results through the receiver-operating-characteris-
tic analysis. The method achieved sensitivity 97.1% and
specificity 96.8% but the cross-validation setting has not
been described in details. In [46], the training group has
been used to discover a pattern that discriminated can-
cer from non-cancer group. This pattern has then been
used to classify an independent set of 38 patients with
the prostate cancer and 228 patients with the benign
conditions. The obtained specificity is low. The predic-
tive matrix factorization method [1] yielded significantly
worse result than the method proposed here. In [45] a
clustering based method for feature selection from mass
spectrometry data is derived combining k-means cluster-
ing and genetic algorithm. Despite a three-fold cross-
validation, the reported error was 28.97%. Figure 4
shows sensitivities and specificities estimated by 100
independent two-fold cross-validations using linear
SVM classifier on components selected by the method
proposed here. For each M the optimal values of the
parameters l and Δθ (obtained by cross-validation) have
been used to obtain results shown in Figure 4. Increas-
ing a postulated number of components from 2 to 5
increased accuracy from 97.4% to 98.3%. Thus, better
accuracy is achieved with the smaller number of features
(m/z ratios) contained in selected components.
1.7 Colon cancer prediction from gene expression profiles
Gene expression profiles of 40 colon cancer and 22 nor-
mal colon tissue samples obtained by an Affymetrix oli-
gonucleotide array [48], have been also used for
validation and comparative performance analysis of pro-
posed feature extraction method. Gene expression pro-
files have been downloaded from [49]. Original data
produced by oligonucleotide array contained more than
6500 genes but only 2000 high-intensity genes have
been used for cluster analysis in [48] and are provided
for download on the cited website. The proposed SCA-
based approach to feature extraction/component selec-
tion has been used to extract four sets of components
with up- and down-regulated genes and with the overall
number of components M assumed to be 2, 3, 4 and 5.
The linear SVM classifier has been applied to groups of
Figure 4 prostate cancer prediction. Sensitivities (a) and specificities (b) (with standard deviations as error bars) estimated in prostate cancer
prediction from protein expression levels using 100 independent two-fold cross-validations and linear SVM classifier. Four sets of selected
components were extracted by SCA-based factorization using LMMs (2a) and (2b) with control reference (c.r.) and disease reference (d.r.) samples
respectively, where the overall number of components M has been set to 2 (red bars), 3 (green bars), 4 (blue bars) and 5 (magenta bars).
Optimal values of the parameters l and Δθwere used for each M. Performance improvement is visible when number of components is increased
from 2 to 5.
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gene expression levels for specific combinations of para-
meters Δθ, l and M. The best result in terms of sensi-
tivity and specificity for each M has been selected and
shown in Figure 5. The complete list of results obtained
by linear SVM classifier is presented in the Additional
File 4. An increased number of postulated components
M did not decrease accuracy but it yielded components
selected for classification with reduced number of genes.
This is verified in Figure 6 which shows component
with up-regulated genes sdisease
control extracted from a cancer
labelled sample w.r.t. the control reference for assumed
number of components M =2a n dM =4 .T h u s ,i ti s
confirmed again that an increased M yields less complex
components that (following the principle of parsimony),
should be preferred over the more complex ones
obtained by smaller M. In order to (possibly) increase
the prediction accuracy, we have applied nonlinear,
polynomial and RBF SVM classifiers to the two groups
of the four sets of components that yielded the best
results with the linear SVM classifier: M =2( Δθ =1
0)
and M =4( l =1 0
-2lmax and Δθ =5
0). The polynomial
SVM classifier has been cross-validated for degree of the
polynomial equal to d = 2, 3 and 4. The RBF SVM clas-
sifier κ(x,y) = exp


−
 x − y
 2
2

2σ2

has been cross-
validated for the variance s
2 in the range 5 × 10
2 to 1.5
×1 0
3 in steps of 10
2. The best result has been obtained
with s
2 =1 . 2×1 0
3 for M =2a n dw i t hs
2 =1 . 0×1 0
3
for M = 4. An achieved accuracy is comparable with the
accuracy obtained by other state-of-the-art results
reported. That is shown in Table 4 as well as in the
Additional File 5. A predictive matrix factorization
method [1] yielded slightly better results here, but it has
shown significantly worse result in the cases of ovarian
(see Table 2) and prostate (see Table 3) cancers. Gene
discovery method [2] has been applied for three values
of the threshold cu Î {2, 2.5, 3} used to select up-regu-
lated genes. Maximum ap o s t e r i o r iprobability has been
used for an assignment of genes to each of the three
components containing up-, down regulated and differ-
entially not expressed genes. Thus for each threshold
value the two components were obtained for training a
classifier. The logarithm with the base 10 has been
applied to gene folding values prior gene discovery/
selection took place. The best result reported in Table 4
has been obtained for a component containing up-regu-
lated genes with cu = 2.0 and an RBF SVM classifier,
whereas s
2 has been cross-validated in the range 10
2 to
10
3 in steps of 10
2. The best result has been obtained
for s
2 =5×1 0
2. The gene discovery method [2] outper-
formed slightly the method proposed here. However as
opposed to the proposed method, the gene discovery
method [2] is not applicable to the analysis of mass
spectra. The gene selection method in [15] is a model
driven trying to take into account the genes’ group
behaviours and interactions by developing an ensemble
dependence model (EDM). The microarray dataset is
clustered first. The EDM is based on modelling depen-
dencies that represent inter-cluster relationships. Inter-
cluster dependence matrix is the basis for discrimination
between cancerous and non-cancerous samples. Classifi-
cation accuracy of 85% reported in [15] is very close to
the one obtained by the SCA-based method proposed
here. However, while SCA-based performance has been
assessed through two-fold cross-validation, no cross-
validation details were reported in [15]. Similarly, sensi-
tivity had to be estimated indirectly from Figure 5 in
Figure 5 colon cancer prediction. Sensitivities (a) and specificities (b) (with standard deviations as error bars) estimated in colon cancer
prediction from gene expression levels using 100 independent two-fold cross-validations and linear SVM classifier. Four sets of selected
components were extracted by using LMMs (2a) and (2b) with control reference (c.r.) and disease reference (d.r.) samples respectively, where the
overall number of components M has been set to 2 (red bars), 3 (green bars), 4 (blue bars) and 5 (magenta bars). Optimal values of the
parameters l and Δθwere used for each M. Increasing number of components M did not decrease prediction accuracy but did reduce the
number of features (genes) in components used for classification (see Figure 6).
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Page 14 of 17[48]. The method in [50] combines a recursive feature
extraction and the linear SVM to yield accuracy of
82.5%. This is also less accurate than what has been
achieved by the method proposed. Moreover, the very
accuracy reported in [50] has been assessed by a ten-
fold cross-validation only and that is known to yield a
too optimistic performance assessment. In this regard
accuracy reported in [51] can be taken closer to the rea-
listic one since it has been assessed by two-fold cross-
validation. This method, as [50], again combines recur-
sive feature elimination with the SVM, but it is taking
additionally into account the parameter C. A reported
accuracy of 88.84% is slightly better than the one
obtained by the method proposed here. However, the
proposed method is a classifier independent one and, as
demonstrated in sections 1.5 and 1.6, it yields good
results on cancer diagnosis from proteomic datasets as
well.
Conclusions
This work presents a feature extraction/component
selection method based on innovative additive linear
mixture model of a sample (protein or gene expression
levels represented respectively by mass spectra or micro-
array data) and sparseness constrained factorization that
operates on a sample(experiment)-by-sample basis. That
is different in respect to the existing methods which fac-
torize complete dataset simultaneously. The sample
model is comprised of a test sample and a reference
sample representing disease and/or control group. Each
sample is decomposed into several components selected
automatically (the number is determined by cross-vali-
dation), without using label information, as disease-,
control specific and differentially not expressed. An
automatic selection is based on mixing angles which are
estimated from each sample directly. Hence, due to the
locality of decomposition, the strength of the expression
of each feature can vary from sample to sample. How-
ever, the feature can still be allocated to the same (dis-
ease or control specific) component in different samples.
As opposed to that, feature allocation/selection
algorithms that operate on a whole dataset simulta-
neously try to optimize a single threshold for the whole
dataset. Selected components can be used for classifica-
tion due to the fact that labelled information is not used
in the selection. Moreover, disease specific component
(s) can also be used for further biomarker related analy-
sis. As opposed to the existing matrix factorization
methods, such disease specific component can be
obtained from one sample (experiment) only. By postu-
lating one or more components with differentially not
expressed features the methody i e l d sl e s sc o m p l e xd i s -
ease and control specific components that are composed
of smaller number of features with higher discriminative
power. This has been demonstrated to improve predic-
tion accuracy. Moreover, decomposing sample with one
or more components with indifferent features performs
(indirectly) sample adaptive preprocessing related to
removal of features that do not significantly vary across
the sample population. The proposed feature extraction/
component selection method is demonstrated on the
real world proteomic datasets used for prediction of the
ovarian and prostate cancers as well as on the genomic
dataset used for the colon cancer prediction. Results
obtained by 100 two-fold cross-validations are compared
favourably against most of the state-of-the-art methods
cited in the literature and used for cancer prediction on
the same datasets.
Additional material
Additional file 1: code with implementation of proposed feature
extraction/component selection method.
Additional file 2: classification results obtained by the linear SVM
applied to disease and control specific components extracted from
the ovarian cancer dataset for various combination of parameters
M, l and Δθ.
Additional file 3: classification results obtained by the linear SVM
applied to disease and control specific components extracted from
the prostate cancer dataset for various combination of parameters
M, l and Δθ.
Additional file 4: classification results obtained by the linear SVM
applied to disease and control specific components extracted from
Figure 6 colon cancer feature vectors. Component containing up-regulated genes extracted from a cancerous sample w.r.t. to a control
reference sample using LMM (2a): a) assumed number of components M = 2; b) assumed number of components M =4 .
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Page 15 of 17the colon cancer dataset for various combination of parameters M,
l and Δθ.
Additional file 5: best classification results obtained by the RBF
SVM applied to disease and control specific components extracted
from the colon cancer dataset for M =4 ,l =1 0
-2lmax and Δθ =5
0
and M = 2 and Δθ =1
0.
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